Medical device company Cerevast Therapeutics has topped off a Series C funding round with an additional $1.4 million.
Cerevast, based in Redmond, raised a total of $11.4 million in the latest round, according to a new filing with the U.S. Securities and Exchange Commission. In December, Cerevast disclosed it had raised $10 million of the total.
Cerevast says it will use the proceeds largely for its ongoing Phase 3 clinical study of Clotbust ER, a device for treating stroke patients with ultrasound. Ultrasound transducers are embedded in what looks like a headband that’s attached to a patient’s head, and “can be rapidly and easily deployed by virtually any emergency room staff to safely administer the ultrasound energy” to treat stroke-causing clots in the brain.
Cerevast was founded in 2009 after it purchased the assets of ImaRx Therapeutics, and is led by CEO Bradford Zakes.